Get the Stockscreener App
1.15
5.74%
-0.07
After Hours:
1.18
0.03
+2.61%
Opus Genetics Inc stock is traded at $1.15, with a volume of 273.14K.
It is down -5.74% in the last 24 hours and down -19.01% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$1.22
Open:
$1.21
24h Volume:
273.14K
Relative Volume:
1.24
Market Cap:
$36.14M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-1.055
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
+3.60%
1M Performance:
-19.01%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.125
$1.2447
1-Week Range:
$1.06
$1.2699
52-Week Range:
$0.81
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
37000 GRAND RIVER AVE., FARMINGTON HILLS
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.15 | 36.14M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc. - The Manila Times
Portland Investment Counsel Inc. Recognized at the FundGrade A+® Awards - The Manila Times
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
Opus Genetics sets April 30 for 2025 Annual Meeting - MSN
Opus Genetics revises executive compensation agreements - Investing.com India
Avinger Inc adjourns Special Meeting due to lack of quorum - MSN
Opus Genetics revises executive compensation agreements By Investing.com - Investing.com Canada
Opus Genetics Enhances Executive Severance Packages - TipRanks
Applied DNA Sciences fails to secure shareholder vote - MSN
Harmony Biosciences Reports Strong Revenue Growth and Outlines Ambitious 2025 Strategy - MSN
Toyota Tsusho (OTCMKTS:TYHOF) Shares Down 18.7% – Should You Sell? - Defense World
Opus Genetics launches $40M at-the-market equity program - Investing.com
NeoGenomics CEO Chris Smith to retire - MSN
Opus Genetics CEO Magrath George buys $97,600 in stock - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Opus Genetics aligns with FDA on Phase 3 trial for diabetic retinopathy drug - Investing.com Canada
IRD stock touches 52-week low at $0.84 amid market challenges - Investing.com India
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy - The Manila Times
Opus Genetics Secures FDA Agreement for Pivotal Diabetic Retinopathy Treatment Trial - StockTitan
Ocuphire Pharma Sets End-of-Phase 2 Meeting With FDA in Q4 to Discuss Diabetic Retinopathy Treatment - Marketscreener.com
Opus Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a - GlobeNewswire
Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 - Marketscreener.com
AXT Inc (AXTI) Could Be Worth Considering For The Next Few Weeks - Stocks Register
At $0.76 Price, Cumulus Media Inc (CMLS) Is Sitting And Waiting - Stocks Register
Analysts Update Their Estimates For Alpha Teknova Inc - Stocks Register
Analysts Provide An Important Insights On Hallador Energy Co (HNRG) - Stocks Register
Hippo Holdings Inc (HIPO): Major Improvements, Worth A Look - Stocks Register
Telomir Pharmaceuticals Inc (TELO) Recovers 37.62% From Low: Are We There Yet? - Stocks Register
Journey Medical Corp (DERM) Should Be Considered For The Next Few Weeks - Stocks Register
The9 Limited ADR (NCTY)’S 0.19% Increase Makes It Worth Considering Again - Stocks Register
Platinum Group Metals Ltd (PLG): Be Patient, You Will Learn - Stocks Register
Nexgel Inc (NXGL) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Cel-Sci Corp (CVM) Stock Behavior Is Not Predictable - Stocks Register
Opus Genetics president Benjamin Yerxa acquires $9,834 in stock - Investing.com India
Opus Genetics president Benjamin Yerxa acquires $9,834 in stock By Investing.com - Investing.com Canada
Opus Genetics Inc CEO George Magrath Purchases 100,000 Shares - GuruFocus.com
FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World
Opus Genetics Inc (IRD) Quarterly 10-Q Report - Quartzy
Opus Genetics reinstated with a Buy at H.C. Wainwright - Yahoo Finance
IRD stock touches 52-week low at $1.07 amid market challenges - Investing.com India
Opus Genetics (IRD) Stock Chart and Price History 2024 - MarketBeat
Wainwright sets stock target on Opus Genetics, cites 2025 catalysts By Investing.com - Investing.com UK
Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Opus Genetics Reports $7.5 Million Net Loss in Third Quarter - Vision Monday
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Hafnia Ltd (NYSE: HAFN) Drops -3.00%, Turning Investors Away - Stocks Register
If You Don’t Buy Zimmer Biomet Holdings Inc (NYSE: ZBH) Now, You’ll Regret It Later - Stocks Register
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. |
May 22 '24 |
Buy |
1.76 |
3,500 |
6,178 |
78,500 |
| Magrath George | Chief Executive Officer |
May 17 '24 |
Buy |
1.75 |
5,000 |
8,772 |
430,000 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Mar 21 '24 |
Buy |
2.05 |
2,000 |
4,100 |
2,000 |
| Jhaveri Nirav S. | Chief Financial Officer |
Mar 21 '24 |
Buy |
2.10 |
10,000 |
21,000 |
150,000 |
| Magrath George | Chief Executive Officer |
Mar 18 '24 |
Buy |
1.96 |
25,000 |
49,050 |
425,000 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):